A group of scientists including Sidra Medicine’s Chief Research Officer, Dr. Francesco M. Marincola, has discovered that a gene called Bach2 may play a central role in the development of a range of allergic and autoimmune diseases, such as multiple sclerosis, asthma, Crohn’s disease, celiac disease, and type-1 diabetes. The research has implications for the development of new therapies to target cancer. The findings were published in the prestigious journal Nature on June 2nd, 2013
The authors suggest that these findings may have implications for cancer treatment, since cancers use regulatory T cells to prevent their own destruction by antitumor immune responses. The team is now working toward manipulating the activity of the Bach2 gene with the goal of developing a new cancer immunotherapy. As this study was conducted in mice, it must be replicated in humans before its findings can be applied in a clinical setting.
“Sidra Medicine will continue along this line of research through direct collaboration with the National Institutes of Health (NIH) to extend this observation toward its practical application to modulate the outcome of immune diseases by genetically regulating the function of Bach2 or other factors that regulate immune cell function,” said Sidra Medicine’s Chief Research Officer Dr. Francesco M. Marincola, who was involved in the study. “At Sidra Medicine we will carry out research to expand the scientific community’s understanding of a broad range of diseases that affect women and children around the world. I am delighted that we will be able to use our unique resources and expertise to expand this vital piece of research.”
Sidra Medicine plans to develop a facility where reprogrammable cell therapy can be conducted. A delegation led by David F. Stroncek, MD, Chief of the Cell Processing Section at the NIH will visit Sidra Medicine in June to begin discussing future collaboration in the creation of a reprogrammable cellular therapy facility, which will become a resource for Sidra Medicine’s local, regional and international partners and collaborators.
In autoimmune diseases, the immune system attacks normal cells and tissues in the body that are generally recognized as “self” and do not usually trigger immune responses in patients without autoimmune diseases. Autoimmunity can arise as a consequence of abnormal immune responses in infectious diseases and cancer. The immune system is comprised of a variety of cell types that must act in unison to maintain a healthy balance. White blood cells called ‘CD4+ T cells’ play a dual role within the immune system. Some CD4+ T cells activate immune responses, whereas others, called regulatory T cells, function in the opposite direction by constraining immune responses. This duality is important because uncontrolled immune responses may result in immune system attacks against the body’s own cells and tissues, which occurs in allergic and autoimmune diseases. One of the hallmarks of uncontrolled immune responses is excessive tissue inflammation. Although tissue inflammation is a normal part of immune responses, excessive inflammation can lead to tissue and organ damage and may be potentially lethal. How CD4+ T cells become either activating/inflammatory or regulatory is not well understood, according to the researchers.